Long-term safety of hyaluronidase-facilitated subcutaneous immunoglobulin 10%: a European post-authorization study
Pauline M. Ellerbroek, Leman Yel(Children's Hospital of Philadelphia), P. Martin van Hagen(Erasmus MC), Torsten Witte(Medizinische Hochschule Hannover), Vassilios Lougaris(University of Brescia), Katharina Fielhauer(Baxalta (United States)), Leif G. Hanitsch(Humboldt-Universität zu Berlin), Barbara McCoy(Baxalta (United States)), András Nagy(University of Szeged), Jie Chen(Yan'an University), Pieter van Paassen(Maastricht University Medical Centre)
Cited by 5
Related Papers
Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial
|The Lancet Rheumatology|2020|199
A new molecular classification to drive precision treatment strategies in primary Sjögren’s syndrome
|Nature Communications|2021|166
Characterization of the clinical and immunologic phenotype and management of 157 individuals with 56 distinct heterozygous NFKB1 mutations
|Journal of Allergy and Clinical Immunology|2020|127
Evaluation of Fluoroquinolones for the Prevention of BK Viremia after Renal Transplantation
|Clinical Journal of the American Society of Nephrology|2010|113